3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
10
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Healthy Participants
2
Uterine Cervical Neoplasms
1
Solid Tumour
1
Recurrence
1
Ovarian Neoplasms
1
Moderate Hepatic Impairment
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Endometrial Neoplasms
1
Disease Progression
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Interventions
Dexamethasone
64
Lenalidomide
34
pomalidomide
33
Cyclophosphamide
33
Rituximab
31
Bortezomib
29
venetoclax
27
fludarabine
26
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
16
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Injections
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts